Literature DB >> 10953195

Late-onset SCA2: 33 CAG repeats are sufficient to cause disease.

M Fernandez1, M E McClain, R A Martinez, K Snow, H Lipe, J Ravits, T D Bird, A R La Spada.   

Abstract

SCA-2 is an autosomal dominant inherited disorder characterized by ataxia, slow saccades, and hyporeflexia. The authors evaluated a patient with a mild balance problem with a SCA-2 allele sized at 33 CAG repeats. The authors then ascertained her 91 year-old mother, who showed disease onset at age 86 with an SCA-2 allele of identical size. Their study indicates that 33 CAG repeats can be pathogenic at the SCA-2 locus, though such an allele may produce an extremely late onset and gradual rate of disease progression.

Entities:  

Mesh:

Year:  2000        PMID: 10953195     DOI: 10.1212/wnl.55.4.569

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

1.  Unexpanded and intermediate CAG polymorphisms at the SCA2 locus (ATXN2) in the Cuban population: evidence about the origin of expanded SCA2 alleles.

Authors:  José Miguel Laffita-Mesa; Luis C Velázquez-Pérez; Nieves Santos Falcón; Tania Cruz-Mariño; Yanetza González Zaldívar; Yaimee Vázquez Mojena; Dennis Almaguer-Gotay; Luis Enrique Almaguer Mederos; Roberto Rodríguez Labrada
Journal:  Eur J Hum Genet       Date:  2011-09-21       Impact factor: 4.246

2.  Ataxin-2 repeat-length variation and neurodegeneration.

Authors:  Owen A Ross; Nicola J Rutherford; Matt Baker; Alexandra I Soto-Ortolaza; Minerva M Carrasquillo; Mariely DeJesus-Hernandez; Jennifer Adamson; Ma Li; Kathryn Volkening; Elizabeth Finger; William W Seeley; Kimmo J Hatanpaa; Catherine Lomen-Hoerth; Andrew Kertesz; Eileen H Bigio; Carol Lippa; Bryan K Woodruff; David S Knopman; Charles L White; Jay A Van Gerpen; James F Meschia; Ian R Mackenzie; Kevin Boylan; Bradley F Boeve; Bruce L Miller; Michael J Strong; Ryan J Uitti; Steven G Younkin; Neill R Graff-Radford; Ronald C Petersen; Zbigniew K Wszolek; Dennis W Dickson; Rosa Rademakers
Journal:  Hum Mol Genet       Date:  2011-05-24       Impact factor: 6.150

Review 3.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

4.  Effects of the enlargement of polyglutamine segments on the structure and folding of ataxin-2 and ataxin-3 proteins.

Authors:  Jingran Wen; Daniel R Scoles; Julio C Facelli
Journal:  J Biomol Struct Dyn       Date:  2016-05-20

Review 5.  The roles of proteolysis and nuclear localisation in the toxicity of the polyglutamine diseases. A review.

Authors:  R Walsh; E Storey; D Stefani; L Kelly; V Turnbull
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

6.  Direct evidence that Ataxin-2 is a translational activator mediating cytoplasmic polyadenylation.

Authors:  Hiroto Inagaki; Nao Hosoda; Hitomi Tsuiji; Shin-Ichi Hoshino
Journal:  J Biol Chem       Date:  2020-09-28       Impact factor: 5.157

7.  Large normal and intermediate alleles in the context of SCA2 prenatal diagnosis.

Authors:  Tania Cruz-Mariño; Jose Miguel Laffita-Mesa; Yanetza Gonzalez-Zaldivar; Miguel Velazquez-Santos; Raul Aguilera-Rodriguez; Annelie Estupinan-Rodriguez; Yaime Vazquez-Mojena; Patrick Macleod; Milena Paneque; Luis Velazquez-Perez
Journal:  J Genet Couns       Date:  2013-06-28       Impact factor: 2.537

8.  Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis.

Authors:  Annalese G Neuenschwander; Khanh K Thai; Karla P Figueroa; Stefan M Pulst
Journal:  JAMA Neurol       Date:  2014-12       Impact factor: 18.302

Review 9.  Gene therapy for ALS: A review.

Authors:  Defne A Amado; Beverly L Davidson
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

10.  De novo mutations in ataxin-2 gene and ALS risk.

Authors:  José Miguel Laffita-Mesa; Jorge Michel Rodríguez Pupo; Raciel Moreno Sera; Yaimee Vázquez Mojena; Vivian Kourí; Leonides Laguna-Salvia; Michael Martínez-Godales; José A Valdevila Figueira; Peter O Bauer; Roberto Rodríguez-Labrada; Yanetza González Zaldívar; Martin Paucar; Per Svenningsson; Luís Velázquez Pérez
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.